Healthcare, Consumer Staples Jul 08, 2021 08:27 AM (GMT+8) · EqualOcean
According to the official account of WeChat, China announced today that the NMPA drug control center (CDE) had accepted its anti PD-1 antibody, baichai. ®( Tirizumab injection is a new indication for the treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients who have previously received first-line standard chemotherapy.
Related companies: